ABOS (Acumen Pharmaceuticals) EPS without NRI: $-1.86 (TTM As of Mar. 2026)


ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.36
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals EPS without NRI?

Acumen Pharmaceuticals ABOS +6.79% 34 EPS without NRI is $-1.86 as of Mar. 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,176 Biotechnology companies, Acumen Pharmaceuticals ranks worse than 87.76% on this metric.

Acumen Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.34. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.86.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Acumen Pharmaceuticals's EPS without NRI or its related term are showing as below:

ABOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.1   Med: -39.8   Max: -21.2
Current: -23.4

ABOS's 3-Year EPS without NRI Growth Rate is ranked worse than
87.76% of 1176 companies
in the Biotechnology industry
Industry Median: 16.8 vs ABOS: -23.40

Acumen Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.33. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.86.

Acumen Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2026 was $-0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.86.


Acumen Pharmaceuticals  (NAS:ABOS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Acumen Pharmaceuticals EPS without NRI Related Terms


Acumen Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for Acumen Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acumen Pharmaceuticals EPS without NRI Chart

Acumen Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial -0.97 -1.06 -1.05 -1.74 -1.99

Acumen Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.48 -0.68 -0.43 -0.41 -0.34

ABOS vs QTTB, TNYA, MDWD: EPS without NRI Comparison

For the Biotechnology subindustry, Acumen Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acumen Pharmaceuticals PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's PE Ratio without NRI falls into.


ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-1.86 mean?
Acumen Pharmaceuticals (ABOS) has a EPS without NRI of $-1.86 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Acumen Pharmaceuticals and its competitors. According to the industry distribution chart, Acumen Pharmaceuticals ranks #1032 out of 1176 companies in the Biotechnology industry, placing it in the top 87.8%.
Is Acumen Pharmaceuticals' EPS without NRI too high?
Acumen Pharmaceuticals' current EPS without NRI is $-1.86. Based on the distribution chart, Acumen Pharmaceuticals ranks #1032 out of 1176 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' EPS without NRI compare to QTTB and TNYA?
According to the Biotechnology industry distribution chart, Acumen Pharmaceuticals ranks #1032 out of 1176 companies for EPS without NRI. This places Acumen Pharmaceuticals in the lower half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,176 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Acumen Pharmaceuticals and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acumen Pharmaceuticals's current EPS without NRI is $-1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current EPS without NRI of $-1.86. The current EPS without NRI is $-1.86. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current EPS without NRI is $-1.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36
Price